Preliminary data in preclinical models of severe complex wounds suggests that human VSELs™ (very small embryonic like stem cells) accelerates wound healing. NeoStem hopes to advance into early clinical studies to assess therapeutic potential of VSEL technology.
Early results for the new flu drug FluCide® found to be safe in a non-GLP small animal safety/ toxicology study. These preliminary results support the company’s earlier reports of the FluCide® drug being effective in animal models of different influenza A virus strains. NanoViricides is also developing drugs against HIV/AIDS (HivCide™-I), Dengue (DengueCide™-I), and External Eye Viral disease (EKC-Cide™-I), amongst other viral diseases.
STR has started a clinical trial in Europe for its ACL device and has successfully implanted the device in 7 patients as of October 2013. Their device utilizes a synthetic scaffold that regenerates the entire ligament tissue resulting in better chances of full recovery.
Profound’s unique device for Prostate cancer treatment is currently in Phase I clinical trials in Europe and Canada. Profound has also received FDA approval to conduct clinical trials in U.S that will begin soon in 2013. The company is on fast track to begin commercialization in Europe by 2015.
NEW YORK, Oct. 15, 2013 – OneMedForum announced today that a major theme of its 7th annual healthcare investing conference will be to provide investors with an outlook about how the healthcare system will function post-Obamacare. Moreover, it will also address the new financing opportunities created by the JOBS Act and feature innovatively growing companies that are best positioned to succeed in this new environment.
Orexigen Therapeutics is a biopharmaceutical company that focuses its attention on the treatment of one of the most common diseases in existence today, obesity.
OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15
“InVivo Interim” InVivo (NVIV) President, CEO and CFO Frank Reynolds Resigns; Michael J. Astrue In As Interim CEO and Sean Moran in As Acting CFO […]
Recent challenges to biotechnology companies have been in the form of corporate governance issues, especially those undergoing rapid growth. Two companies in particular, InVivo (NVIV) […]
One of the major obstacles of growth for Internet based Crowdfunding platforms in the U.S. has been the reaction of regulatory authorities. However, two “no-action […]
Copyright © 2024 | WordPress Theme by MH Themes